ABVX · Abivax S.A. · Webcasts, Transcripts & Audio
$73.84
-6.81 (-8.44%)
At close · Nov 20
Return incl. dividend (before tax)
Q4 2023 earnings call transcript
Market Cap
$7.06B
Shares
87.54M
Volume · Nov 20
11.24M
Avg daily vol (3M)
1.13M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Abivax S.A. Webcasts
Earnings calls, investor updates, investor days and conferences for Abivax S.A. (ABVX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-12-14
Abivax S.A. (ABVX) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-12-01
Abivax S.A. (ABVX) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-30
Abivax S.A. (ABVX) November 30, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-09
Abivax S.A. (ABVX) November 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-09-21
Abivax S.A. (ABVX) Q2 2026 Earnings Call
Revenue
1.20M EUR
▲ 9.9% YoY Diluted EPS
-1.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-06-01
Abivax S.A. (ABVX) Q1 2026 Earnings Call
Revenue
1.34M EUR
▲ 35.2% YoY Diluted EPS
-0.61
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-05-11
Abivax S.A. (ABVX) May 11, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-23
Abivax S.A. (ABVX) Q4 2025 Earnings Call
Revenue
440,000 EUR*
▼ 89.8% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q4
2024-01-25
Abivax S.A. (ABVX) Q4 2023 Earnings Call Transcript
Positive tone
Obefazimod Phase 3 ABTECT in ulcerative colitis
Follow-on pipeline candidates and preclinical work
Enrollment / retention and headache management
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–9 of 9 webcasts
Key facts
CIK
1956827
CUSIP
00370M103
13F (30d)
308 filings
297 filers
Visit website
Investor relations